2026-01-02 - Analysis Report
Okay, let's break down this ISRG (Intuitive Surgical Inc.) analysis.

**0) Overview**

We are analyzing Intuitive Surgical Inc. (ISRG), comparing its performance to the S&P 500 (VOO), and evaluating its financial health, recent performance, and market sentiment.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.
*   **Cumulative Return:**
    *   ISRG: 80.65%
    *   VOO: 105.07%
*   **Divergence:** -24.4 (Relative Divergence: 29.2)
*   **Analysis:** ISRG has underperformed the S&P 500 over the period considered, resulting in a negative divergence of 24.4%. The relative divergence of 29.2 suggests this underperformance is closer to the lower end of its historical fluctuation range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha  | Beta | Cap(B)  |
|------------|---------|---------|--------|------|---------|
| 2016-2018  | 166.0%  | 72.0%   | 136.0% | 1.2  | 57.2    |
| 2017-2019  | 156.0%  | 72.0%   | 114.0% | 1.4  | 70.6    |
| 2018-2020  | 90.0%   | 81.1%   | 57.0%  | 1.2  | 97.8    |
| 2019-2021  | 106.0%  | 81.1%   | 30.0%  | 1.2  | 128.8   |
| 2020-2022  | 42.0%   | 84.4%   | 23.0%  | 1.2  | 95.1    |
| 2021-2023  | 35.0%   | 85.6%   | 7.0%   | 1.4  | 120.9   |
| 2022-2024  | 84.0%   | 82.0%   | 53.0%  | 1.3  | 187.1   |
| 2023-2025  | 131.0%  | 75.9%   | 63.0%  | 1.2  | 203.0   |

*   **CAGR:** The Compound Annual Growth Rate is consistently high, indicating strong growth over each three-year period.
*   **MDD:** The Maximum Drawdown figures are substantial, showing significant volatility and potential for large price declines.
*   **Alpha:** Alpha represents the excess return compared to the market (presumably the S&P 500). The positive alpha values indicate that ISRG outperformed the market on a risk-adjusted basis for each period. However, alpha has decreased significantly in recent periods.
*   **Beta:** Beta values around 1.2-1.4 suggest ISRG is more volatile than the market.  A beta of 1.2-1.4 implies that for every 1% move in the S&P 500, ISRG tends to move by 1.2%-1.4%.
*   **Cap(B):** Market capitalization has generally increased across each period.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 566.36
*   **Previous Close:** 572.63
*   **Change:** -1.09
*   **5-day SMA:** 573.87
*   **20-day SMA:** 565.81
*   **60-day SMA:** 538.15

**Analysis:** The price is currently below the 5-day SMA and slightly above the 20-day SMA, suggesting a short-term downtrend that could be stabilizing.  The 60-day SMA is significantly lower, suggesting an overall upward trend in the medium term. The negative change relative to the previous close indicates recent downward pressure.

**3) RSI, PPO, and Hybrid Signal Analysis**

*   **MRI:** 0.9 (Medium Investment Recommended)
*   **RSI:** 56.89 (Neutral - neither overbought nor oversold)
*   **PPO:** -0.11 (Slightly bearish momentum)
*   **Hybrid Signal:** "cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)"  This suggests a strong buy signal based on the hybrid model, indicating a safe investment with high MRI score.
*   **Recent Divergence Change:** -1.3 (Short-term decline)
*   **Expected Return:** 0.0% (No expected excess return compared to S&P 500 long-term)

**Analysis:** The MRI indicates a medium investment recommendation. The RSI suggests neutral momentum. The slightly negative PPO supports the short-term decline indicated by the divergence change. Despite recent weakness, the hybrid signal is strongly bullish. The 0% expected return compared to S&P 500 is concerning, suggesting no significant outperformance is anticipated.

**4) Recent News & Significant Events**

*   **[2025-12-29] Intuitive Surgical Stock (ISRG) Opinions on 2025 Growth Guidance Update:**  This suggests market attention is focused on future growth prospects.
*   **[2025-12-13] Intuitive Surgical Stock Hits Key Support - Buying Opportunity?:** Indicates the stock price has declined to a level where buyers might be interested, potentially leading to a price rebound.
*   **[2026-01-01] Intuitive Surgical stock today: ISRG slips into 2026 as New Year’s Day shuts Wall Street:**  This is just a general market update.
*   **[2026-01-01] Roberts Wealth Advisors LLC Takes Position in Intuitive Surgical, Inc.:** Positive news; institutional investors are buying the stock.
*   **[2025-12-31] Where Will Intuitive Surgical Be in 5 Years?:** Long-term outlook articles can influence investor sentiment.
*   **[2025-12-31] ISRG Stock Today (31 Dec 2025): Technical Indicators in Focus:**  Highlights that technical analysis is relevant to current market perception of ISRG.

**Analysis:**  The news is mixed.  The "buying opportunity" and institutional buying are positive signals. The focus on growth guidance suggests investor sensitivity to future performance.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.06 (~Buy)
*   **Opinions:** 29
*   **Target Price:** 599.60 / 700.00 / 378.00

**Analysis:**  Analysts generally have a positive outlook on ISRG, with a "Buy" consensus. The average target price of $599.60 represents upside potential from the current price of $566.36.  The low target price of $378.00 shows some analysts are very bearish. The lack of recent rating changes suggests analysts haven't significantly altered their views recently.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-10-22 | 1.98 | 2.51 B$     |
| 2025-07-23 | 1.84 | 2.44 B$     |
| 2025-04-23 | 1.95 | 2.25 B$     |
| 2024-10-18 | 1.59 | 2.04 B$     |
| 2025-10-22 | 1.59 | 2.04 B$     |

**Analysis:**  Both EPS and revenue have generally been increasing over the last several quarters, indicating strong growth. There seems to be an error in the table with duplicate entry '2025-10-22'. This needs to be clarified.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $2.51B     | 66.36%        |
| 2025-06-30   | $2.44B     | 66.31%        |
| 2025-03-31   | $2.25B     | 64.69%        |
| 2024-12-31   | $2.41B     | 68.04%        |
| 2024-09-30   | $2.04B     | 67.41%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE   |
|--------------|------------|-------|
| 2025-09-30   | $16.93B    | 4.16% |
| 2025-06-30   | $17.85B    | 3.69% |
| 2025-03-31   | $17.11B    | 4.08% |
| 2024-12-31   | $16.43B    | 4.17% |
| 2024-09-30   | $15.58B    | 3.63% |

**Analysis:** Revenue shows a clear upward trend. The profit margin is exceptionally high and relatively stable, indicating strong pricing power and efficient operations. Equity is also increasing. ROE fluctuates but is generally healthy, showing good returns on shareholders' equity.

**7) Comprehensive Analysis (Summary)**

*   **Performance:** ISRG has underperformed the S&P 500 recently. The current negative divergence is concerning, but the relative divergence shows the underperformance is at the lower end of recent fluctuations.  The decreasing Alpha in recent years is also concerning.
*   **Technicals:** Short-term downtrend indicated by SMA's, RSI is neutral, and PPO shows slight bearish momentum.
*   **Market Sentiment:** Mixed.  Analyst consensus is "Buy," with upside potential based on average target price. However, news also highlights concerns about growth guidance and dependence on technical analysis.
*   **Financials:** Strong and growing revenue, exceptionally high profit margins, increasing equity, and healthy ROE. The company is fundamentally sound.
*   **Recommendation:** ISRG's strong financials and analyst consensus are positive. However, recent underperformance relative to the S&P 500, coupled with the expected return of 0.0%, requires careful consideration. While the hybrid signal suggests a buy, the overall picture points to a hold, but the duplicate entry in the Earnings Analysis table needs to be clarified. If the earnings data is correct, it reinforces the hold position. If it is an error, the analysis could change. Investors should closely monitor the stock's performance and future growth guidance updates and should recognize that despite a "Buy" consensus, the MRI indicates Medium Investment Recommended, highlighting market risks and short term volatility.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.